on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Executes Out-License Deal for Botanical Drug Candidate for Schizophrenia
Jaguar Health, Inc. (NASDAQ:JAGX) has announced an out-licensing agreement with Magdalena Biosciences, Inc. for the development of a botanical drug candidate aimed at treating schizophrenia. The candidate shows antipsychotic activity distinct from existing FDA-approved therapies.
Jaguar will receive 10% of upfront and milestone payments and royalties on sales if the drug receives FDA approval. The U.S. schizophrenia market, projected to reach $8.06 billion by 2030, presents significant commercial potential for the drug.
The joint venture between Jaguar and Filament Health Corp. focuses on developing plant-based prescription medicines. The botanical drug candidate may establish a new class of plant-based antipsychotic compounds.
Jaguar will present at the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. Interested parties can register online to attend.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news